i: Only f or patients who received chemotherapy. To be done at 2nd GM-CSF/TG01 injection after end of chemotherapy (8 weeks after last chemotherapy injection) . j: can be done at day 78 if more appropriate k: For patients who discontinue before the 2 years, a survival follow -up will be performed where possible at week 104. l: Only for patients not starting chemotherapy at all and to be done prior each vaccination (every 4 weeks) m: for patients not starting chemo; to be done every 12 weeks n: For all GM -CSF/TG01 administrations after chemotherapy the patients should be give prophylactic treatment (30 minutes before treatment) to prevent possible occurr ence of allergic reactions . At visits where the patients will receive a DTH injection (TG01) before the GM-CSF/TG01 administration then the prophylactic treatment should be given 30 minutes prior the DTH injection. *: +/- 1 day window for visits in the initial treatment period and for other weekly visits (Initial treatment period or chemotherapy treatment period) **: window of +/ - 1 week for 4 week ly injections and 12 weekly injections ***: Applies also to patients not starting chemotherapy at all and the period will be from week 10 to week 52 CT TG01 -01 Version v10.0 27 June 2018 Confidential 40 / 87 Table 2: Schedule of visits – Concomitant group Page in protocol Screening Initial Treatment Period (1st 3 Cycles of chemotherapy)* Repeat Cycles with chemotherapy* After chemo to W 52 W52-104 Patient end of Study visit** Survival FU Study Week 1 1 1 2 3 4 5 6 7 8 9 10 11 13 17 21 14 18 22 15 19 23 16 20 24 Every 4 weeks** Every 12 weeks ** W104 or 4 weeks after last TG01 / GM- CSFk Every 6 months and at study end** Thereafter ~every 12 months Study Day -84 to -7 -7 1 3 5 8 15 22 29 36 43 50 57 64 71 Cycle D1 Cycle D8 Cycle D15 Cycle D22 TG01 / GM -CSFa 51 to 59 x x x x x x x x x x x xl xl DTH injectionb 51 to 59 x x x x x x x xi xe Gemcitabinec 51 to 59 x x x x x x x x x x x x 5-FU and Leucovoring 51 to 59 x x x x x x x x Informed Consent 60 x Patient eligibility 60 x Demography / Medical History 60 x Resect pancreas 60 x Tumour sample 60 x ECG 61, 68 x <--------------------------------------------------------------------------------- As clinically indicated --------------------------------------------------------------------- ------------------  Physical Exam/ PS 61, 68 x x x x x xe x Vital Signs 61 x x x x x x x x x x x x x x x xf x x Haematology / Chemistryd 61, 68 x x x x x x x x x x x x x xf x x Pregnancy test 61 x Concurrent illness 61 x DTH assessmentb 55, 66 x x x x x x x xi xe Immunology sampled 65, 66 x xj xe x CA19.9 / other biomarkersd 67 x x x x xe x Urinalysis 61, 68 x <------- ------------------------------------------------------------ ------------------------- As clinically indicated ------------------ ---------- -----------------------------------------------  CT/MRI / assess diseaseh 61, 66 x <------------------------------- ------------------------------------------------------------------ Every 6 months ---------------------------------------------------------------  x Adverse events 67, 71 <-------------------------------------------------------------------------------- ----------------- As clinically indicated ----------------------------------------------- ------------------------  Concomitant medications 60, 61 x <------------------------------------------------------------------------------------------------- As cli nically indicated --------------------------------------------- ---------------------------  Survival follow -up X CT TG01 -01 Version v10.0 27 June 2018 Confidential 41 / 87 a: GM-CSF given 10- 15 min before TG01 After end of chemotherapy treatment may be given for up to 2 years or until withdrawal of consent, toxicity or the need for additional treatment for pancreatic cancer whichever is the earliest Patients should be observed for at least 30 minutes after all vaccinations . b: DTH injection should be performed 30 minutes before the GM-CSF/TG01 injection Assessment of DTH injection site to be done 48 hours (+/ - 4 hours) after each GM- CSF/TG01 injections. c: To start within 12 weeks from surgery d: Blood samples to be taken prior to all treatments .